Roche bets again on Io­n­is in Hunt­ing­ton’s, Alzheimer's

Roche is again pair­ing up with its decade­long part­ner Io­n­is Phar­ma­ceu­ti­cals, pay­ing $60 mil­lion up­front for the ex­clu­sive rights to two RNA as­sets, the com­pa­nies said Wednes­day morn­ing.

The deal cen­ters around Hunt­ing­ton’s dis­ease and Alzheimer’s dis­ease. The duo orig­i­nal­ly came to­geth­er in 2013 for an­oth­er Hunt­ing­ton’s pro­gram, tomin­ersen, which is cur­rent­ly in a Phase II study, and again in 2018 for IgA nephropa­thy and a lead­ing cause of blind­ness known as ge­o­graph­ic at­ro­phy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER